BioLife Solutions, Inc. announced that the Hart-Scott-Rodino antitrust waiting period for its proposed acquisition by Repligen Corporation expired on September 3, 2026. Under the merger agreement, BioLife shareholders will receive $11.25 in cash and 0.1442 shares of Repligen common stock per share. The transaction remains subject to customary closing conditions, including approval by BioLife's stockholders at a special meeting scheduled for October 5, 2026. BioLife Solutions operates in the biotechnology industry, providing cell therapy solutions and services.

BioLife Solutions reported second quarter 2026 total revenue of $28.5 million, a 21% increase from the prior year period. GAAP net income was $45.1 million, driven by a $42.4 million non-cash income tax benefit from the release of a valuation allowance, while adjusted EBITDA reached $7.4 million. The filing highlights that Repligen will acquire BioLife for an enterprise value of approximately $1.5 billion through a combination of cash and stock, with closing expected in the fourth quarter of 2026. BioLife Solutions is a developer and supplier of cell processing tools and services for the cell and gene therapy market.

BioLife Solutions filed a Form 8-K under Item 7.01 (Regulation FD Disclosure) on August 3, 2026, to furnish an email from Chairman and CEO Rod Roderick de Greef circulating a video message from Repligen Corporation President and CEO Olivier Loeillot. The communication provides additional information regarding the previously announced Agreement and Plan of Merger dated July 21, 2026, under which Repligen will acquire BioLife through a two-step merger process. Repligen management emphasized that the transaction remains subject to regulatory and shareholder approvals, with closing expected in the fourth quarter of 2026, while both entities continue to operate independently. This filing serves as a disclosure of forward-looking statements and strategic rationale for the acquisition. BioLife Solutions operates in the biotechnology industry, providing cell processing tools and biopreservation media.

On July 21, 2026, BioLife Solutions, Inc. entered into a definitive merger agreement to be acquired by Repligen Corporation for a total enterprise value of approximately $1.5 billion. BioLife stockholders will receive $11.25 in cash and 0.1442 shares of Repligen common stock per share, representing a total value of $31.00 per share. The transaction is expected to close in the fourth quarter of 2026, subject to stockholder approval and regulatory clearances. Additionally, BioLife reported preliminary unaudited second quarter 2026 revenue of $28.5 million, a 21% increase year-over-year. The company operates in the life sciences industry, developing and supplying cell processing tools and biopreservation media for the cell and gene therapy market.